AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00415961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoStar Paclitaxel Drug-Eluting Coronary Stent System
Description: CoStar Paclitaxel Drug-Eluting Coronary Stent System
Study NCT02629965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium
Description: fixed dose combination
Study NCT02629965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol
Description: fixed dose combination
Study NCT02629965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Study NCT03343977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel 50mg/m2
Description: 50 mg/m2 of docetaxel will be given on day 1 every 14 days
Study NCT03343977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel 75mg/m2
Description: 75 mg/m2 of docetaxel will be given on day 1 every 21 days
Study NCT01726478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.5 units Oxytocin
Description: Administration of 2.5 units of oxytocin after clamping of umbilical cord
Study NCT01726478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 10 units Oxytocin
Description: Administration of 10 units of oxytocin after clamping of umbilical cord
Study NCT02390219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor
Study NCT02390219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Study NCT00667433 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Raltegravir + Truvada
Description: Raltegravir 400 mg tablet BID PO X 104 weeks; Truvada 200/300 mg tablet once a day PO x 104 weeks
Study NCT05529719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Pilates Exercises
Description: Participants in the experimental group were included in the clinical Pilates intervention, which consisted of three weekly sessions for 50 minutes for 12 weeks. Clinical pilates sessions were performed by a clinically Pilates-certified instructor and a physiotherapist. The intervention was divided into three sections. Each session started with the warm-up section. The warm-up part started with breathing exercises, pelvic tilt centering, activation of deep trunk and pelvic floor muscles, and joint mobility. The Clinical Pilates exercises section consisted of matte level strength and flexibility exercises involving the trunk, upper and lower extremities. Finally, a cooling part was done that included some flexibility exercises.
Study NCT02060552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diacerein
Description: oral administration of IL-1βinhibitory
Study NCT02060552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine is a toxic natural product and secondary metabolite, originally extracted from plants of the genus Colchicum (autumn crocus, Colchicum autumnale, also known as meadow saffron). It was used originally to treat rheumatic complaints, especially gout as the positive control
Study NCT02060552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Febuxostat
Description: A urate lowering drug, an inhibitor of xanthine oxidase that is indicated for use in the treatment of hyperuricemia and gout
Study NCT02060552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: A urate lowering drug, an inhibitor of xanthine oxidase that is indicated for use in the treatment of hyperuricemia and gout
Study NCT04068571 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: I-PUSH
Description: Innovative partnership for universal and sustainable healthcare
Study NCT02348970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ONIRIS®
Description: sleeping test
Study NCT02348970 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TALI
Description: sleeping test
Study NCT01241162 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cell vaccine with adjuvant
Description: Week 1:~Decitabine (DAC): 10 mg/m2/day IV (Mon-Fri)~Weeks 2 and 3:~Vaccine: 3-5 E6 peptide pulsed DC (Mon)~Hiltonol applied topically to vaccine site before and after vaccination
Study NCT03171506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Participants in the usual care plus ketogenic diet group will receive usual care plus dietary counseling in accordance with a ketogenic diet such that \~5% energy comes from carbohydrate, 25% energy from protein, and 70% energy from fat for the duration of the 12 week study.
Study NCT03171506 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AND diet
Description: Participants in the usual care plus AND diet group will receive usual care plus dietary counseling in accordance with the Academy of Nutrition and Dietetics guidelines in 2013 for the duration of the 12 week study.
Study NCT01027637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 mm vessel clips
Description: evenly placed vessel clips placed at surgery and tracked by ultrasound
Study NCT02169661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Burger and Beetroot Study
Description: 50% fat, 10% beetroot extract
Study NCT04322227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foliglurax 10 mg (treatment A)
Description: Foliglurax 10 mg, (BID) capsules, orally
Study NCT04322227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foliglurax 30 mg (treatment B)
Description: Foliglurax 30 mg, BID capsules, orally
Study NCT04322227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (treatment C)
Description: Placebo, BID capsules, orally
Study NCT00796211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRx-197
Description: CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
Study NCT00796211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRx-197
Description: CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
Study NCT00796211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nortriptyline
Description: 0.1% nortriptyline HCl topical cream
Study NCT00796211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol
Description: 0.005% calcipotriol topical cream
Study NCT00796211 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle of CRx-197 topical cream (placebo)
Study NCT02809534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib p.o. qd
Study NCT00333333 — intervention group
Intervention type: PROCEDURE
Intervention: Cord blood
Description: Cord blood will be obtained at the time of delivery.
Study NCT01588587 — intervention group
Intervention type: DRUG
Intervention: Sitagliptin
Description: The dosage, frequency and duration for each sitagliptin are variant.
Study NCT01731444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Study NCT01588587 — intervention group
Intervention type: DRUG
Intervention: Alogliptin
Description: The dosage, frequency and duration for each alogliptin are variant.
Study NCT01588587 — intervention group
Intervention type: DRUG
Intervention: Vildagliptin
Description: The dosage, frequency and duration for each vildagliptin are variant.
Study NCT02107937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVAC/OvCa with Standard of Care
Description: DCVAC/OvCa is the experimental therapy added on to Carboplatin and Paclitaxel
Study NCT02107937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVAC/OvCa sequentially chemotherapy
Description: DCVAC/OvCa added sequentially after Carboplatin and Paclitaxel
Study NCT02107937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy
Study NCT01586624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib, Selumetinib
Description: Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 25 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 25 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment.
Study NCT01586624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib, Selumetinib
Description: Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment.
Study NCT01586624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib, Selumetinib
Description: Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 75 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 75 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment.
Study NCT01586624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib, Selumetinib
Description: Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 100 mg of selumetinib OD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 100 mg of selumetinib OD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment.
Study NCT01586624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib, Selumetinib
Description: Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 125 mg of selumetinib OD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 125 mg of selumetinib OD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment.
Study NCT01586624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib, Selumetinib
Description: Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 200 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 200 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 200 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment.
Study NCT01586624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib, Selumetinib
Description: Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 2) followed by vandetanib steady state dose of 300 mg OD (Days 3 to 14) followed by vandetanib steady state dose of 300 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 300 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment.
Study NCT03577652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor, 90mg, 90mg twice daily
Study NCT04393155 — intervention group
Intervention type: OTHER
Intervention: COVID-19+ observational
Description: This is observational -- there is no intervention
Study NCT02458898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Text Message Reminders
Description: 45 unique text messages designed by the Stanford Pediatric Gastroenterology physicians and nutritionists
Study NCT01425931 — intervention group
Intervention type: PROCEDURE
Intervention: Heart Lung machine
Description: measurement of microcirculation with O2C device
Study NCT01284244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uresta pessary
Description: Participants randomized to the Uresta group will be fitted with device before immediately before performing the pad test. The Uresta pessary is made of medical grade rubber that has been extensively tested for safety. It is bell-shaped, with a narrow tip that allows for easy insertion into the vagina in a similar fashion to a tampon. The device can be easily inserted, and removed by a patient for use when needed. The Uresta comes in 3 sizes. Fitting starts with insertion of the smallest size. If urine leakage continues with valsalva or a cough stress test, it can be replaced by one size larger, until leakage is stopped. If the device prevents the patient from being able to void or is uncomfortable due to its size, the smaller size is replaced. Following the pad test, the participant will be given the opportunity to keep the device for continued use, or remove it if desired.
Study NCT01284244 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Silastic ring
Description: The silastic ring is a plastic flexible ring similar to that used to administer vaginal estrogen (Estring). It is well tolerated and would not contain any medications. Immediately before performing the pad test, it would be placed high in the vagina, away from the urethra. It would be removed immediately after the pad test. Draping will conceal from the patient which device was inserted.
Study NCT02631044 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCAR017 (lisocabtagene maraleucel) single-dose schedule
Description: Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
Study NCT02631044 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCAR017 (lisocabtagene maraleucel) 2-dose schedule
Description: Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon product availability, participants will receive study treatment consisting of lymphodepleting chemotherapy followed by two IV doses of JCAR017.
Study NCT03861390 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 60 mg Prednisone
Description: Immediately following exit from the wood smoke chamber, subjects will receive 60 mg of prednisone per randomization schema
Study NCT04016597 — intervention group
Intervention type: DEVICE
Intervention: Jaeger Masterscreen TM
Description: Single-breath nitric oxide lung diffusing capacity
Study NCT04016597 — intervention group
Intervention type: DEVICE
Intervention: HypAir Medisoft
Description: Single-breath nitric oxide lung diffusing capacity
Study NCT03861390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 60 mg Prednisone
Description: Immediately following exit from the wood smoke chamber, subjects will receive 60 mg of prednisone per randomization schema
Study NCT03861390 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Immediately following exit from the wood smoke chamber, subjects will receive a matching placebo to the 60 mg of prednisone per randomization schema
Study NCT00827034 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Warfarin
Description: A: a single oral dose of warfarin 25 mg administered on Day 1 of the relevant dosing period, as tablets.
Study NCT00827034 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dimebon
Description: B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
Study NCT00827034 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Warfarin
Description: B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
Study NCT04578262 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epley Manoeuvre
Description: This manoeuvre is constituted by five steps. In the first step, while the patient is in supine posture the head will be positioned 45 degrees turned towards the unaffected ear and the head slightly overhang on the edge of the couch. In this second step maintaining the previous position of the head, physiotherapist will turn head 45 degrees turned towards the affected ear. Next, in the third step, the whole body will turn until is located 135 degrees from the baseline supine position. In the fourth step, while the head keeps turned to the affected ear the subject will be incorporated until he is sitting. In the fifth step, while the subject is seated with the head in neutral position the chin will be bended 20 degrees. Each procedure will be held among 30 seconds or two minutes, while the dizziness or the nystagmus vanish. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain).
Study NCT04578262 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Manoeuvre
Description: The sham manoeuvre consist is going to star with the participant in a neutral seated position. Sum to it, head is rotated 45 degrees towards the unaffected vestibule. After that, the participant will be guided by the physiotherapist to a lateral decubitus position towards the affected side on which his nose will be pointing above. To conclude, the seated position will be reached again without head rotation. Each position of the sham manoeuvre will be maintained along one minute. During all the process the videonystagmography glasses will be dressed by participants and they will be indicated not to close eyes in the intervention. After the execution of the manoeuvre, also this group will be evaluated 48 hours after. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain).
Study NCT01914796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-06412562
Description: Single doses, given by oral solution, starting at 0.5 mg up to a possible maximum of 150 mg. The subject will have been fasted for 10 hours prior to the single dose. Two doses, 120 mg and 150 mg, will be split into 3 doses such that the total dose is given over 8 hours (i.e. t = 0, 4, and 8 hours). For each dosing period, 2 subjects will be given a placebo as a comparator. One dose will be given in the fed state.
Study NCT01914796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-06412562
Description: It is believed that for increasing doses of this compound the eye blink rate (EBR) will also increase. This arm will use EBR measurement technology to verify this hypothesis. In each dosing period, 4 subjects will be given a placebo as a comparator.
Study NCT03176680 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid therapy optimization
Description: colloid 250 mL bolus to increase stroke volume index (SVI). If the increase of SVI is more than 10% of baseline, repeat the bolus. If the increase of SVI is less than 10% of baseline, stop the bolus.
Study NCT01306162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate plus dronedarone
Description: dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose
Study NCT01306162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: 150 mg as single dose
Study NCT01306162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate plus dronedarone
Description: dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose (staggered administration)
Study NCT01306162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate plus dronedarone
Description: dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid
Study NCT04582409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSY244
Description: HSY244 concentrate solution for injection via intravenous infusion
Study NCT01306162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate plus dronedarone
Description: dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid (staggered administration)
Study NCT02626715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reduced-Intensity Conditioning Regimen
Description: Campath (alemtuzumab) - drug class: monoclonal antibody Droxia (hydroxyurea) - drug class: antimetabolite Fludara (fludarabine) - drug class: antimetabolite Alkeran (melphalan) - drug class: alkylating agent Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent